Annual Meeting 2016: Preliminary results of the AIM trial of ibrutinib and venetoclax in mantle cell lymphoma

Constantine Tam, MBBS, MD from the Peter MacCallum Cancer Centre, Melbourne, Australia gives an overview of the preliminary results of the Phase II AIM study of ibrutinib and venetoclax (ABT-199) in relapsed/refractory mantle cell lymphoma (NCT02471391) presented at the American Society of Oncology (ASCO) 2016 Annual Meeting in Chicago, IL. Dr Tam outlines how of the eight patients who have completed a four month course, five are in complete remission (CR), two patients in partial remission, and one patient did not respond. Dr Tam further discusses the promise of this drug combination and the associated toxicities.